Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Meliessa Hennessy"'
Autor:
Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gomez, Maria Baer, Carlo Gambacorti-Passerini, James Mccloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Huilan Yao, Tammie Yeh, Josep Maria Ribera
Publikováno v:
HemaSphere, Vol 7, p e68516d0 (2023)
Externí odkaz:
https://doaj.org/article/f833a33b51b945e094c5af6cc6ac5e78
Autor:
Murtuza Bharmal, Sandra Nolte, Mickaël Henry-Szatkowski, Meliessa Hennessy, Michael Schlichting
Publikováno v:
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-11 (2020)
Abstract Objectives For valid and reliable assessment of patients’ Health-Related Quality of Life (HRQoL), it is crucial to use psychometrically robust instruments. In the context of rare diseases such as Merkel cell carcinoma (MCC), validated dise
Externí odkaz:
https://doaj.org/article/3d267f6c7dc74a6588b142923ce2b5a3
Autor:
Murtuza Bharmal, Isabelle Guillemin, Alexia Marrel, Benoit Arnould, Jérémy Lambert, Meliessa Hennessy, Fatoumata Fofana
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-10 (2018)
Abstract Background Demonstrating treatment benefits within clinical trials in the context of rare diseases is often methodologically and practically challenging. Mixed methods research offers an approach to overcome these challenges by combining qua
Externí odkaz:
https://doaj.org/article/bcde5692cb2e4751a7dc376ed31a1121
Autor:
Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-7 (2018)
Abstract Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-
Externí odkaz:
https://doaj.org/article/8702b9ace3ed4ea195be94aaa6b2d065
Autor:
Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Taft Leonard, David Gomez-Almaguer, Maria R. Baer, Carlo Gambacorti-Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Geraldo Rocha, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Bingxia Wang, Meliessa Hennessy, Alexander Vorog, Niti Patel, Josep-Maria Ribera
Publikováno v:
Journal of Clinical Oncology. 41:398868-398868
398868 Background: The standard of care in patients (pts) with newly diagnosed (dx) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is BCR::ABL1 tyrosine kinase inhibitors (TKIs) in combination with chemotherapy (chemo) or s
Autor:
Lia Gore, Mignon Loh, Ching-Hon Pui, Yousif Matloub, Michael J. Hanley, Jichang Du, Meliessa Hennessy, Muriel Granier, Andrea Biondi, Lewis Silverman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S190-S191
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To report integrated electrocardiogram (ECG) summary and exposure–QTc analyses for avelumab, a human immunoglobulin G1 monoclonal antibody that binds programmed cell death 1 ligand 1, to assess potential effects on cardiac repolarization. M
Autor:
Lia Gore, Mignon Loh, Ching-Hon Pui, Yousif Matloub, Michael J. Hanley, Jichang Du, Meliessa Hennessy, Muriel Granier, Andrea Biondi, Lewis Silverman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S123
Autor:
Lewis B. Silverman, Mignon L. Loh, Yousif Matloub, Michael J. Hanley, Muriel Granier, Lia Gore, Jichang Du, Meliessa Hennessy, Andrea Biondi, Ching-Hon Pui
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S271-S272
Context: Ph+ ALL is associated with improved outcomes when tyrosine kinase inhibitors (TKIs) are added to chemotherapy, with 5-year event-free survival (EFS) and overall survival (OS) for newly diagnosed patients of 60% and 86%, respectively. Ponatin
Autor:
Sandra Nolte, Meliessa Hennessy, Michael Schlichting, Mickaël Henry-Szatkowski, Murtuza Bharmal
Publikováno v:
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-11 (2020)
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-11 (2020)
Objectives For valid and reliable assessment of patients’ Health-Related Quality of Life (HRQoL), it is crucial to use psychometrically robust instruments. In the context of rare diseases such as Merkel cell carcinoma (MCC), validated disease-speci